By investigating multiple inflammatory mediators (CD93, CD36, STAT3, NF-Kappa B, and TLR2/4), our results highlight the therapeutic potential of hAAT in treating kidney inflammation (Figure 8). This evidence concerns the gene CD93 and nephritis.